These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36915888)

  • 1. Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.
    Ying Y; Wang Z; Tan Y; Cao H; Gao H; Zhang Z; Zeng S; Xu C
    Transl Androl Urol; 2023 Feb; 12(2):176-186. PubMed ID: 36915888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
    Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
    Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
    Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
    Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Terlević R; Ulamec M; Štimac G; Murgić J; Krušlin B
    Biomol Biomed; 2023 Nov; 23(6):968-975. PubMed ID: 37389960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
    Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
    Koll FJ; Schwarz A; Köllermann J; Banek S; Kluth L; Wittler C; Bankov K; Döring C; Becker N; Chun FKH; Wild PJ; Reis H
    Front Med (Lausanne); 2022; 9():875142. PubMed ID: 35783619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
    Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
    Pérez-Montiel D; Olivares-Mundo A; Jiménez-Ríos MA; Morera CS; Scavuzzo A; Orozco-Mora A; Prada D; Cantú-de León D
    Ann Diagn Pathol; 2023 Apr; 63():152081. PubMed ID: 36680930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Kim JM; Choi E; Sung SH; Kang H; Park S
    Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
    Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
    Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
    Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
    Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.